Subscribe to PRO at just Rs.33 per month. Use code SUPERPRO
Last Updated : Jul 24, 2020 04:41 PM IST | Source: Moneycontrol.com

Buy Alembic Pharma; target of Rs 1140: ICICI Direct

ICICI Direct is bullish on Alembic Pharma has recommended buy rating on the stock with a target price of Rs 1140 in its research report dated July 23, 2020.

Broker Research
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Alembic Pharma

Revenues grew robust 41.4% YoY to Rs 1341 crore due to 72.8% YoY growth in US to Rs 596 crore. Additionally, better-than-expected sales in 1) RoW (up 62% YoY) as serialisation issues especially in Europe have been addressed, 2) API segment (up 54%) due to Azithromycin and other opportunities propelled revenue growth. Domestic formulations de-grew 5.6% to Rs 306 crore. EBITDA margins improved 587 bps YoY to 30.4% mainly due to lower other expenditure amid lower promotional, travelling and R&D costs. EBITDA grew 81.1% YoY to Rs 407.4 crore. Adjusted PAT grew 103.7% YoY to Rs 302 crore mainly due to strong operational performance.


Although this is fraught with a new set of challenges, Alembic now looks in much better shape to withstand those challenges. We maintain BUY and arrive at a target price of Rs 1140 based on 22x FY22E EPS of Rs 51.9.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
First Published on Jul 24, 2020 04:41 pm